Work

Bispecific engager immunotherapy targeting the retained portion of MUC16 (MUC16) is efficacious against ovarian cancer

Year: 2019

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2019.04.136

Authors: O. Yeku, T.D. Rao, T. Purdon, R.J. Brentjens, D. Spriggs

Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954078083

FWCI:

Cites:

Cited by:

Related to: 10